Expanding Direct-To-Patient Options, BMS/Pfizer Add Eliquis To Cost Plus Drugs Portal
Bristol Myers Squibb and Pfizer already sell their market-leading anticoagulant Eliquis through corporate direct-to-patients portals, but aim to reach even more cash-paying underinsured patients.
Scrip - April 24, 2026

FcRn Inhibitors: A Promising Pipeline-In-A-Product Frontier
Three FcRn inhibitors are on the market and more are in development, with long-term commercial growth expected to come through indication expansion. Now the question is will they deliver on their pipeline-in-a-product promise?
Scrip - April 24, 2026

Why Viridian Wants In On FcRns Despite Being Late To The Game
The company is studying two FcRn inhibitors in early clinical development and spoke to Scrip about the competitive market.
Scrip - April 24, 2026

Pipeline Watch: Twelve Approvals And Nine Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 24, 2026

Hansa’s Europe Miss For Lead Drug Raises US Launch Stakes
Hansa’s launch preparations are underway ahead of an expected US FDA decision on imlifidase, its desensitization therapy for kidney transplant patients, later this year.
Scrip - April 24, 2026

CEO: Bayer Leaner And Faster But Not Out Of The Woods
Bill Anderson has told stockholders that two years into a major restructuring plan, the German company was "leaner and faster" than before but there were still "big milestones and decisions ahead."
Scrip - April 24, 2026

Ipsen Bets On Pipeline Catalysts And Rare Disease Momentum To Power 2026 Growth
After posting a decent set of financials, Ipsen is banking on upcoming pipeline catalysts and portfolio diversification to sustain growth beyond its legacy franchise.
Scrip - April 24, 2026

Astellas Settles Another Mirabegron Lawsuit, With MSN Pharma
The agreement follows a series of earlier legal settlements over generic versions of overactive bladder drug Myrbetriq in the US market.
Scrip - April 24, 2026

Double Billing: Regeneron MFN Deal Announced Along With Approval Of Its Gene Therapy
Treatment for deafness is the first gene therapy approved under the FDA Commissioner’s National Priority Voucher program.
Scrip - April 24, 2026

Edwards Lifesciences Raises Guidance After TAVR Growth Leads Strong Q1
Edwards Lifesciences beat first-quarter expectations in every segment and raised its full-year outlook. The TAVR segment saw 11% growth as major competitors showed weakness – and with the possibility of new Medicare coverage on the horizon, the expansion may continue.
Medtech Insight - April 24, 2026

Nectero’s EAST System Slows AAA Growth In 90% Of Patients Over Two Years
Boston Scientific-backed company’s PGG therapy limited the growth of abdominal aortic aneurysms, with 90% of AAAs growing more slowly than expected; a Phase II/III trial is ongoing.
Medtech Insight - April 24, 2026

MedCon Day 3: Tarver Continues To Hammer Home Use Of Medical Devices
CDRH director Michelle Tarver closed out MedCon 2026 by highlighting the center’s focus on patients and meeting the challenges presented by a rapidly evolving medtech landscape. She also discussed the center’s home health initiative and noted the importance of digital health.
Medtech Insight - April 24, 2026

FreeStyle Libre 3 Recall: 7 Deaths, 860 Injuries, and Now Complaints From India
Abbott's FreeStyle Libre 3 recall – linked with 860 serious injuries, seven deaths, Class I FDA classification – describes sensors reading lower than actual glucose levels. An Indian physician says three of his sensors showed the same issue, while Abbott says Indian sensors meet global standards.
Medtech Insight - April 24, 2026

FDA Issues Early Alert On Medline Syringes
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026

EU Unlocks New Funding For Health AI Projects
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026

Thermo Fisher Raises Guidance As Q1 Results Dodge Tariff Concerns
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026

US FDA Finds Banned Chemical In Six Gel Nail Polish Removers
FDA testing of gel nail polish removers found six products containing banned ingredient methylene chloride.
HBW Insight - April 25, 2026

Biocon Secures Health Canada Approval For Two Denosumab Biosimilars
Following two more approvals from Health Canada, biosimilars Bosaya and Vevzuo are ready to compete for their market share of denosumab success.
Generics Bulletin - April 24, 2026

Europe Widens Competition Path For Generic Peptides
Europe’s top court has ruled that synthetic medicines may use the EU generic pathway even when the reference product is a biologic, provided Article 10 criteria are met, in a decision with potentially significant implications for peptide competition.
Generics Bulletin - April 24, 2026

EU Nod Arrives For Viatris’s Ibrance Rival
As Viatris received a positive opinion from the EMA’s CHMP for its palbociclib generic, Intas also racked up an endorsement for the region's latest biosimilar rival to Lucentis.
Generics Bulletin - April 24, 2026

Towa Builds Further Backup Network For Drug Shortages
Towa has agreed a manufacturing pact with Sanwa Kagaku Kenkyusho to add backup production capacity, outsource 700 million tablets by FY2028 and strengthen Japan’s off-patent medicines supply through a broader networked manufacturing strategy.
Generics Bulletin - April 24, 2026

Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026

Pharma’s Pipeline Size Dipped In 2025
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026

The 10-80-10 Investment Rule: Preparation Is All
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026